Cetera Investment Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Cetera Investment Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$392K	Sell	127,695 -1,309	-1%	-$5.06K	﹤0.01%	3738
2025 Q4	$528K	Buy	129,004 +1,582	+1%	+$7.84K	﹤0.01%	3387
2025 Q3	$622K	Buy	127,422 +33,145	+35%	+$174K	﹤0.01%	3205
2025 Q2	$477K	Buy	94,277 +18,489	+24%	+$90.8K	﹤0.01%	3007
2025 Q1	$401K	Buy	75,788 +13,955	+23%	+$102K	﹤0.01%	3033
2024 Q4	$418K	Buy	61,833 +13,751	+29%	+$92.5K	﹤0.01%	2819
2024 Q3	$317K	Sell	48,082 -3,107	-6%	-$22.3K	﹤0.01%	3019
2024 Q2	$384K	Buy	51,189 +4,896	+11%	+$42.7K	﹤0.01%	2804
2024 Q1	$462K	Buy	46,293 +33,521	+262%	+$373K	﹤0.01%	2661
2023 Q4	$126K	Buy	+12,772	New	+$91.1K	﹤0.01%	2119

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cetera Investment Advisers's RXRX Position: Q1 2026 in Review

Cetera Investment Advisers reduced its Recursion Pharmaceuticals (RXRX) stake by 1% in Q1 2026, selling an estimated $5.06K and leaving 127,695 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #3738.

Cetera Investment Advisers first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $622K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Cetera Investment Advisers held 127,695 shares of Recursion Pharmaceuticals worth $392K as of Q1 2026.
Cetera Investment Advisers sold 1,309 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.06K.
Recursion Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3738 holding.
Cetera Investment Advisers first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Cetera Investment Advisers's Recursion Pharmaceuticals position peaked at $622K in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.